Anumigilimab

Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation[1][2].

Product Specifications

CAS Number

[2416593-08-1]

Product Name Alternative

CSL-324

UNSPSC

12352203

Target

C-Fms; JAK; STAT

Type

Inhibitory Antibodies

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/anumigilimab.html

Purity

98.43

Solubility

10 mM in DMSO

Smiles

[Anumigilimab]

Molecular Weight

(143.86 kDa)

References & Citations

[1]Markota Čagalj A, et al. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int J Mol Sci. 2022 Mar 29;23 (7) :3753. |[2]Rosales Santillan M, et al. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther. 2020 Jun;20 (6) :621-633. |[3]Scalzo-Inguanti K, et al., A neutralizing anti-G-CSFR antibody blocks G-CSF-induced neutrophilia without inducing neutropenia in nonhuman primates. J Leukoc Biol. 2017 Aug;102 (2) :537-549.